Systems Biological Assessment of Statin Effect on Vaccine Responses
NCT06024096 is a phase 4 interventional trial sponsored by Emory University. As of 21 Nov 2026, it is completed. It studies Atorvastatin and Quadrivalent seasonal influenza vaccine in Vaccine Response. The registry lists an enrollment of 63 participants at 1 site in 1 country. The registry lists a start date of 20 Sept 2023 and a primary completion date of 16 Dec 2024. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06024096 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 63 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Vaccine Response |
| Drugs | Atorvastatin and Quadrivalent seasonal influenza vaccine |
| Start | 20 Sept 2023 |
| Primary completion | 16 Dec 2024 |
| Study completion | 16 Dec 2024 |
| Last update posted | 14 Jan 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Daniel S. Graciaa, MD, MPH, MSc
Emory University
Principal Investigator - Varun Phadke, MD
Emory University
Principal Investigator - Vin Tangpricha, MD, PhD
Emory University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hope Clinic
Atlanta
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06024096
Each answer restates registry values shown on this page.
What is NCT06024096?
NCT06024096 is a phase 4 interventional trial sponsored by Emory University. It studies Atorvastatin and Quadrivalent seasonal influenza vaccine in Vaccine Response.
Who leads NCT06024096?
The registry names Daniel S. Graciaa, MD, MPH, MSc (principal investigator, Emory University), Nadine Rouphael, MD (principal investigator, Emory University), Varun Phadke, MD (principal investigator, Emory University) and 1 more official as overall officials.
Where does NCT06024096 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06024096 study?
The registered drug and biological interventions are Atorvastatin and Quadrivalent seasonal influenza vaccine.
When did NCT06024096 end?
The registry lists a primary completion date of 16 Dec 2024 and a study completion date of 16 Dec 2024. The sponsor last updated the record on 14 Jan 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.